Europe and its multiple entry points present a real challenge for early-stage validation. Its structural fragmentation between numerous countries – and as many ways of driving innovation – offers no single default pathway to founders which can lead to diluted efforts, scattered pilots and difficulty building a coherent, pan-European story for potential partners. How can companies choose their clinical and market entry points to optimise data creation and strengthen credibility? What validation strategies help build investor confidence? Experts will provide insights into concrete pathways and best practices to navigate early-stage validation across Europe.
Navigating early-stage validation in a structurally fragmented Europe: Pathways and best practices
Moderated roundtable discussion consisting in an exchange of ideas and perspectives by international experts to delve into the latest challenges of the sector.
- 9:15 AM
- 10:00 AM
A toolbox session is designed to provide practical skills, easy-to-follow guidelines and take-home tools which delegates can put into practice to deal with their current issues.